kwashiorkor: A syndrome produced by severe protein deficiency, characterized by retarded growth, changes in skin and hair pigment, edema, and pathologic changes in the liver, including fatty infiltration, necrosis, and fibrosis. The word is a local name in Gold Coast, Africa, meaning 'displaced child'. Although first reported from Africa, kwashiorkor is now known throughout the world, but mainly in the tropics and subtropics. It is considered to be related to marasmus. (From Dorland, 27th ed)
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
80 |
4. Check minimum number of eventsNone |
80 |
5. Include endpointsNone |
80 |
6. Filter based on genotype QC (FinnGen only) |
80 |
Control definitions (FinnGen only)
- Control exclude
- E4_MALNUTRITION
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E40-E46
- Name in latin
- Malnutritio gravis ex deficientia proteino-energetica
Similar endpoints
↥List of similar endpoints to
Marasmic kwashiorkor
based on the number of shared cases.
Similar with more cases:
- Malnutrition
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1073 | 584 | 487 |
| Only index persons | 804 | 455 | 349 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 58.77 | 60.88 | 56.20 |
| Only index persons | 62.87 | 64.42 | 60.86 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 80 | 48 | 32 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 56.70 | 54.98 | 59.28 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 73
- Matched controls
- 728
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E42
ICD-10 Finland
Marasmic kwashiorkor
+∞
104.9
73
*
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
67.1
14.5
16
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
8.5
13.4
33
64
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
12.9
12.7
23
25
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
5.5
10.5
40
131
Z98.8
ICD-10 Finland
Other specified postsurgical states
47.0
10.3
12
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.4
8.4
47
212
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
10.4
8.3
16
19
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
50.6
7.9
9
*
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
28.5
7.8
10
*
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
6.1
7.8
22
48
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.5
7.4
23
56
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.1
7.1
24
64
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
11.7
6.8
12
12
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
5.9
6.7
19
41
127
Kela drug reimbursment
Transplant complication
20.2
6.4
9
5
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
20.2
6.4
9
5
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
29.5
6.4
8
*
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
5.8
6.3
18
39
R63.8
ICD-10 Finland
Other symptoms and signs concerning food and fluid intake
+∞
6.3
6
*
RD210
NOMESCO Finland
NA
11.5
6.3
11
11
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
5.8
6.1
17
36
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
22
39
7.40
12.75
1.7
1.6
—
—
—
0
0
18
33
6.75
9.97
17.2
5.2
1.5
1.6
%
0.19
18
33
18
33
6.75
9.97
17.2
5.2
0.8
0.7
%
0.92
18
33
32
99
4.72
9.96
2.7
1.6
1693.2
1226.1
nmol/l
1.85
27
71
50
217
4.48
9.91
4.8
3.4
2.3
2.4
mmol/l
0.30
45
185
21
46
5.83
9.73
16.9
6.2
116.8
121.8
g/l
0.44
21
46
17
31
6.69
9.43
10.2
7.5
24.3
24.5
mmol/l
0.06
17
31
63
338
5.07
9.06
29.8
8.5
1.2
1.2
mmol/l
3.57
57
292
13
20
7.57
8.34
2.5
1.5
—
—
—
0
0
10
12
9.38
7.75
1.4
1.8
—
—
—
0
0
15
30
5.92
7.52
33.7
18.3
1.3
1.5
mg/l
0.36
15
30
29
105
3.76
7.00
4.5
2.7
2.2
2.5
g/l
1.20
29
93
39
177
3.35
6.56
7.7
3.8
0.0
0.0
estimate
0.00
14
59
29
114
3.42
6.08
4.6
3.7
2.8
0.7
e6/l
0.95
24
70
11
20
6.22
5.99
5.0
2.0
—
—
—
0
0
11
20
6.22
5.99
3.7
2.2
—
—
—
0
0
11
20
6.22
5.99
1.6
1.2
—
—
—
0
0
56
332
3.29
5.75
7.9
4.0
0.0
0.0
estimate
0.00
16
59
21
69
3.77
5.73
15.0
6.8
—
—
—
0
0
11
21
5.91
5.70
1.6
1.2
—
—
—
0
0
12
26
5.25
5.46
26.2
8.5
0.6
0.7
%
0.45
12
26
12
26
5.25
5.46
26.2
8.5
1.2
1.5
%
0.42
12
26
20
67
3.65
5.28
1.8
6.2
211.9
250.0
u/l
0.99
20
67
22
79
3.46
5.23
4.7
4.4
11.8
8.1
umol/l
0.20
17
69
19
62
3.71
5.20
3.7
1.9
1.9
1.3
%
1.54
19
56
44
238
2.89
5.14
8.7
4.0
—
—
—
0
0
28
118
3.11
5.14
1.6
1.8
498.1
488.6
pmol/l
0.05
23
100
12
28
4.87
5.02
4.4
15.0
81.4
93.3
%
0.95
12
28
13
33
4.51
4.93
5.5
4.0
41.8
46.9
%
0.27
13
33
9
10
9.96
4.92
1.4
1.6
—
—
—
0
0
50
296
2.84
4.83
7.0
4.1
—
—
—
0
0
54
335
2.88
4.73
8.1
3.9
0.0
0.0
estimate
0.00
15
63
17
55
3.66
4.69
4.8
3.5
—
—
—
0
0
53
327
2.84
4.67
10.0
5.7
0.0
0.0
estimate
0.00
16
60
42
234
2.67
4.47
2.8
1.9
92.3
100.1
pmol/l
0.44
23
103
24
102
2.93
4.26
3.1
1.9
—
—
—
0
0
13
38
3.89
4.10
1.6
1.2
—
—
—
0
0
10
24
4.62
4.02
3.5
2.6
—
—
—
0
0
10
24
4.62
4.02
3.6
1.9
—
—
—
0
0
19
74
3.06
3.90
2.5
1.7
—
—
—
0
0
19
75
3.01
3.80
3.1
1.8
—
—
—
0
0
60
421
2.70
3.69
22.8
10.9
3.7
3.9
e9/l
0.30
55
364
19
79
2.84
3.46
46.9
12.8
25.4
24.5
mmol/l
0.59
19
79
28
145
2.43
3.29
5.9
2.6
—
—
—
0
0
41
252
2.29
3.25
8.4
3.8
—
—
—
0
0
9
20
4.93
3.22
3.4
2.0
—
—
—
0
0
8
16
5.43
3.14
2.4
1.3
—
—
—
0
0
6
8
7.99
3.11
1.3
1.3
—
—
—
0
0
7
12
6.27
3.09
2.6
1.3
—
—
—
0
0
9
23
4.27
2.87
4.8
4.7
199.0
180.2
%
—
9
23
6
11
5.79
2.59
2.0
1.3
—
—
—
0
0
6
11
5.79
2.59
2.8
1.4
—
—
—
0
0
35
220
2.05
2.46
4.5
3.9
15.2
33.9
ng/l
1.22
29
151
7
17
4.40
2.42
2.1
2.2
—
—
—
0
0
14
61
2.57
2.30
31.4
12.1
9.8
9.5
kpa
0.23
14
55
6
15
4.23
2.08
3.7
1.6
—
—
—
0
0
5
11
4.77
1.97
2.0
2.1
—
—
—
0
0
5
12
4.37
1.85
1.6
1.3
—
—
—
0
0
5
13
4.03
1.74
3.2
2.2
—
—
—
0
0
5
13
4.03
1.74
3.4
1.5
—
—
—
0
0
16
86
2.08
1.65
35.4
9.6
4.9
5.1
kpa
0.49
16
78
5
14
3.73
1.64
1.4
1.4
—
—
—
0
0
6
23
2.73
1.39
1.2
1.7
32.3
37.6
u/l
—
6
18
5
18
2.89
1.30
1.6
1.9
602.8
1.5
e6/l
—
5
13
8
37
2.29
1.25
1.8
1.4
—
—
—
0
0
73
661
2.19
1.24
43.3
14.9
27.1
23.3
mg/l
0.54
66
520
5
22
2.35
1.05
1.6
1.5
171.0
378.5
mu/l
—
5
22
0
28
0.00
1.00
0.0
1.1
—
3.3
—
0
18
25
181
1.55
0.96
1.4
1.6
0.9
1.7
u/ml
—
9
41
0
27
0.00
0.79
0.0
1.7
—
—
—
0
0
5
24
2.15
0.76
2.4
2.0
—
—
—
0
0
0
21
0.00
0.61
0.0
2.2
—
—
—
0
0
72
678
1.62
0.60
46.5
15.9
64.9
71.9
umol/l
1.40
72
678
0
22
0.00
0.60
0.0
1.5
—
1.5
—
0
14
6
38
1.62
0.55
2.5
1.5
—
—
—
0
0
7
49
1.47
0.47
3.1
2.4
14.7
13.0
nmol/l
—
7
44
0
15
0.00
0.41
0.0
1.1
—
5.2
—
0
9
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.6
—
—
—
0
0
58
543
1.25
0.33
26.8
13.1
92.2
81.6
ml/min/173m2
3.28
51
427
15
123
1.27
0.28
4.2
4.2
25.4
19.9
%
—
7
51
13
156
0.80
0.24
1.3
1.8
—
—
—
0
0
5
38
1.34
0.23
10.4
2.8
0.2
0.1
e6/l
—
5
38
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
1.8
—
0
6
6
49
1.24
0.20
1.2
1.0
—
—
—
0
0
18
160
1.16
0.15
5.7
2.9
305.0
5074.6
umol/l
0.77
18
135
5
45
1.12
0.10
1.6
2.0
—
—
—
0
0
47
460
1.05
0.03
2.9
3.6
—
—
—
0
0
11
107
1.03
0.00
1.7
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
20.3
—
0
6
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
0.3
—
0
5
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
7.1
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
12.4
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
6
61
0.98
0.00
2.2
2.1
—
—
—
0
0
6
69
0.86
0.00
2.2
2.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_MARAKWASH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_MARAKWASH | 5.458 [2.91, 10.24] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.121 |
During the follow-up period (1.1.1998 — 31.12.2019), 139 out of 423 females with E4_MARAKWASH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_MARAKWASH | 5.927 [2.85, 12.32] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 143 out of 376 males with E4_MARAKWASH died.
Mortality risk
Mortality risk for people of age
years, who have E4_MARAKWASH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.551% | 1.038% |
| 5 | 3.196% | 6.602% |
| 10 | 7.482% | 16.39% |
| 15 | 14.462% | 28.837% |
| 20 | 23.039% | 44.041% |
Relationships between endpoints
↥Index endpoint: E4_MARAKWASH – Marasmic kwashiorkor
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data